(CercleFinance.com) – GlaxoSmithKline announced Thursday that a phase 2 clinical study concerning its monoclonal antibody otilimab in the treatment of patients hospitalized for a Covid infection had not reached a level of statistical significance.
GSK nevertheless points out that the data collected in the context of the trial show that in participants over 70 years of age, 65% of patients were alive and free from respiratory failure after one month in the otilimab group, against 45.9% in the control group.
After two months of treatment, the difference in mortality is also notable, since 26% of patients over 70 in the otilimab group had died compared to 40.4% in the other group.
In order to confirm these results, the laboratory says it wants to recruit 350 additional patients over the age of 70, recalling that the age group in question now represents more than 70% of deaths linked to Covid.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
–
